Watch BRGX. Know when insiders buy.
One email the day a filing lands. Free.
BRGX
BIOREGENX, INC.
0.01
−0.00 −31.25%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $5.3MP/E —DIV YIELD —FCF YIELD —REV TTM $1.8M −23.4%NET INCOME −$1.3MNET DEBT $1.1M52W 0.01 – 0.03SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2026 · Mar 31 | $426K | −17.3% | 81.7% | −$50K | −$26K | — | 0.00 | $27K | — | — | May 20 |
| Q4 2025 · Dec 31derived | $386K | −16.3% | 82.7% | −$936K | −$1M | — | 0.00 | $70K | $3K | $67K | Apr 15 |
| Q3 2025 · Sep 30 | $508K | −14.8% | 84.0% | −$8K | −$81K | — | 0.00 | −$72K | $6K | −$78K | Nov 14 |
| Q2 2025 · Jun 30 | $446K | −39.2% | 79.0% | −$107K | −$178K | — | 0.00 | $3K | $0 | $3K | Aug 14 |
| Q1 2025 · Mar 31 | $515K | −6.3% | 78.8% | −$193K | −$267K | — | 0.00 | $38K | $0 | $38K | May 20 |
| Q4 2024 · Dec 31derived | $460K | −32.1% | 70.1% | −$18.3M | −$18.4M | — | -0.02 | −$11K | $0 | −$11K | Apr 15 |
| Q3 2024 · Sep 30 | $596K | −25.0% | 80.8% | −$327K | −$395K | — | 0.00 | −$31K | $0 | −$31K | Nov 14 |
| Q2 2024 · Jun 30 | $734K | −15.0% | 64.0% | −$1M | −$1.1M | — | 0.00 | −$177K | $0 | −$177K | Aug 14 |
| Q1 2024 · Mar 31 | $550K | — | 69.9% | −$3.1M | −$3.2M | — | 0.00 | −$104K | $189K | −$294K | May 15 |
| Q4 2023 · Dec 31derived | $678K | — | 55.8% | −$212K | −$257K | — | 0.00 | −$246K | $0 | −$246K | Apr 16 |
| Q3 2023 · Sep 30 | $795K | — | 71.9% | −$2.5M | −$2.5M | — | 0.00 | −$283K | $0 | −$283K | Nov 14 |
| Q2 2023 · Jun 30 | $863K | — | 69.3% | −$545K | −$594K | — | 0.00 | −$649K | $0 | −$649K | Oct 9 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1.9M | 81.1% | −$1.2M | −$1.5M | -83.2% | 0.00 | $39K | $9K | $30K | — | — |
| FY2024 · to Dec 31 | $2.3M | 70.9% | −$22.8M | −$23.1M | -985.2% | -0.03 | −$324K | $189K | −$514K | — | — |
| FY2023 · to Dec 31 | $3.4M | 67.8% | −$3.4M | −$3.6M | -105.5% | -0.01 | −$1.5M | $0 | −$1.5M | — | — |
| FY2022 · to Dec 31 | $42K | 100.0% | −$78K | −$78K | -185.7% | 0.00 | −$65K | — | — | — | — |
| FY2021 · to Dec 31 | $199K | 99.7% | −$165K | −$97K | -48.8% | 0.00 | −$120K | — | — | — | — |
Every number comes from BIOREGENX, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.